

ASX RELEASE | OSTEOPORE LIMITED

Osteopore granted patent for ‘smart’ 3D biomimetic scaffolds in China, creating R&D opportunities in the region

Highlights:

- *The patent in China, co-developed with researchers from Nanyang Technological University, Singapore (NTU Singapore), covers Osteopore’s next generation scaffolds that facilitate faster bone growth.*
- *The composite material, previously also granted approval by the European Patent Office, creates more research and developmental opportunities in the Chinese market and allows Osteopore to tap into local expertise as part of its product innovation process.*
- *This marks a further important step in Osteopore’s access to the lucrative Chinese market which currently accounts for 18% of the global craniofacial market, estimated to be worth around AU\$ 2.2b.*

2 November 2021: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), an Australian and Singapore based global leader in the manufacture of innovative implants on a commercial scale empowering natural tissue regeneration, is pleased to announce that the Chinese patent office has granted Patent NO. CN107206120 FOR “BIORESORBABLE-MAGNESIUM COMPOSITE”. The patent, co-developed with researchers from NTU, describes the process by which a magnesium filler comprised of a soluble magnesium salt – magnesium phosphate ($Mg_3(PO_4)_2$) – is produced as a thin film, and when combined with a suitable polymer, is used to produce ‘smart’ three-dimensional biomimetic scaffolds without requiring solvents or heat.

This third-generation bone implant technology enhances Osteopore’s product portfolio which extends the use of polycaprolactone (PCL) through the blending of PCL and tricalcium phosphate (TCP). Magnesium is known for promoting strong bone growth. The addition of soluble magnesium salts in the material, combined with PCL-TCP, is expected to enhance the bone regeneration process.

The patent supports Osteopore’s involvement with the Chinese research and surgical community by creating more collaborative commercial and research and development opportunities in the region. China currently accounts for 18% of the global craniofacial market, estimated to be worth around AU\$ 2.2b.

Osteopore’s CEO, Khoon Seng Goh, said “We recognise the importance of being a part of the local community in driving product innovation and adoption. We look forward to engaging with skilled researchers in China to further develop our next generation implants and aim to make this innovation available to Chinese surgeons and patients.”

“This step is a logical complement to the previously announced Suzhou business registration and provides another plank in Osteopore’s emerging presence in the lucrative Chinese market” added Osteopore’s Chairman, Mark Leong.

“This exciting material combination opens up the opportunity for us to further demonstrate the mechanics of *in-situ* Tissue Engineering through our products. Our technology has the potential to achieve active regeneration and provides our surgeons with tools to achieve favourable clinical outcomes in patients” said Dr Jing Lim, Osteopore’s CTO.

President's Chair in Chemical and Biomedical Engineering at NTU Singapore and co-inventor of the patent, Prof Swee Hin Teoh said, “What we aimed at, was to help the patient grow back their bone structure in the fastest possible time, so we found a way to embed magnesium needed for bone growth within the scaffold material, which can help to accelerate the process while the scaffold is being reabsorbed—a two in one solution.”

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Carl Runde

Chief Financial Officer

Osteopore Limited

+61 400 118 017

carl_runde@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company empowering natural tissue regeneration by commercialising a range of bespoke products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.

Forward Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Osteopore Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.